SLNO vs. INMD, CNMD, BLFS, RYTM, LRMR, EDAP, FONR, RMTI, LIVN, and ITGR
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include InMode (INMD), CONMED (CNMD), BioLife Solutions (BLFS), Rhythm Pharmaceuticals (RYTM), Larimar Therapeutics (LRMR), Edap Tms (EDAP), FONAR (FONR), Rockwell Medical (RMTI), LivaNova (LIVN), and Integer (ITGR). These companies are all part of the "medical" sector.
InMode (NASDAQ:INMD) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.
InMode currently has a consensus target price of $32.80, suggesting a potential upside of 81.22%. Soleno Therapeutics has a consensus target price of $58.33, suggesting a potential upside of 29.66%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe InMode is more favorable than Soleno Therapeutics.
InMode has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the S&P 500.
68.0% of InMode shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 23.7% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Soleno Therapeutics had 5 more articles in the media than InMode. MarketBeat recorded 13 mentions for Soleno Therapeutics and 8 mentions for InMode. InMode's average media sentiment score of 0.60 beat Soleno Therapeutics' score of 0.42 indicating that Soleno Therapeutics is being referred to more favorably in the news media.
InMode has a net margin of 38.84% compared to InMode's net margin of 0.00%. Soleno Therapeutics' return on equity of 26.15% beat InMode's return on equity.
Soleno Therapeutics received 141 more outperform votes than InMode when rated by MarketBeat users. However, 75.12% of users gave InMode an outperform vote while only 71.29% of users gave Soleno Therapeutics an outperform vote.
InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
Summary
InMode beats Soleno Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
